Nanopore Diagnostics

About:

Developing a rapid bacterial diagnostic test to ensure physicians know exactly what they are treating before making an antibiotic decision

Website: http://www.nanoporedx.com

Twitter/X: nanoporedx

Top Investors: National Science Foundation, Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship, Missouri Technology Corporation

Description:

Nanopore Diagnostics develops bacterial diagnostic tests to ensure physicians know exactly what they are treating before making an antibiotic decision. It helps decrease healthcare costs by ensuring physicians are fully informed before needing to make therapeutic decisions. Their sensitive and portable core technology, the iNDxer, will enable microbiology lab quality testing to be conducted right at a patient’s side. The iNDxer counts dilute amounts of nucleic acid biomarkers in minimally processed samples. The iNDxer bacterial diagnostic tests targets RNA markers specific to pathogenic bacteria; the number of harmful microbes in a sample can therefore be determined simply counting these markers. Nanopore Diagnostics is a U.S.-based company that was founded in 2012 by Tom Cohen.